Currently, the agents used to treat underlying inflammation of ocular diseases include anti-inflammatory agents such as corticosteroids, systemic anti-TNFα agents such as adalimumab (Humira®), and immunosuppressives (e.g., cyclosporine A), which can cause cataracts, glaucoma, susceptibility to infections and cancer, and other side effects. The gene discussed is TNF; the disease is cataract.